Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.638.960.675.250 [Categoria DeCS]
Referências encontradas : 15602 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1561 ir para página                         

  1 / 15602 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29298978
[Au] Autor:Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
[Ad] Endereço:Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA. suinlee@cs.washington.edu.
[Ti] Título:A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
[So] Source:Nat Commun;9(1):42, 2018 01 03.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cancers that appear pathologically similar often respond differently to the same drug regimens. Methods to better match patients to drugs are in high demand. We demonstrate a promising approach to identify robust molecular markers for targeted treatment of acute myeloid leukemia (AML) by introducing: data from 30 AML patients including genome-wide gene expression profiles and in vitro sensitivity to 160 chemotherapy drugs, a computational method to identify reliable gene expression markers for drug sensitivity by incorporating multi-omic prior information relevant to each gene's potential to drive cancer. We show that our method outperforms several state-of-the-art approaches in identifying molecular markers replicated in validation data and predicting drug sensitivity accurately. Finally, we identify SMARCA4 as a marker and driver of sensitivity to topoisomerase II inhibitors, mitoxantrone, and etoposide, in AML by showing that cell lines transduced to have high SMARCA4 expression reveal dramatically increased sensitivity to these agents.
[Mh] Termos MeSH primário: DNA Helicases/genética
Resistência a Medicamentos Antineoplásicos/genética
Leucemia Mieloide Aguda/genética
Aprendizado de Máquina
Proteínas Nucleares/genética
Medicina de Precisão/métodos
Fatores de Transcrição/genética
[Mh] Termos MeSH secundário: Algoritmos
Antineoplásicos/farmacologia
Antineoplásicos/uso terapêutico
Biomarcadores Tumorais/metabolismo
Linhagem Celular
Conjuntos de Dados como Assunto
Etoposídeo/farmacologia
Etoposídeo/uso terapêutico
Seres Humanos
Leucemia Mieloide Aguda/tratamento farmacológico
Inibidores da Topoisomerase II/farmacologia
Inibidores da Topoisomerase II/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Nuclear Proteins); 0 (Topoisomerase II Inhibitors); 0 (Transcription Factors); 6PLQ3CP4P3 (Etoposide); EC 3.6.1.- (SMARCA4 protein, human); EC 3.6.4.- (DNA Helicases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180105
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02465-5


  2 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390336
[Au] Autor:Lovisari F; Terzi V; Lippi MG; Brioschi PR; Fumagalli R
[Ad] Endereço:Department of Anesthesia and Critical Care, ASST Grande Ospedale Metropolitano Niguarda. P.zza Ospedale Maggiore, Milan.
[Ti] Título:Hemophagocytic lymphohistiocytosis complicated by multiorgan failure: A case report.
[So] Source:Medicine (Baltimore);96(50):e9198, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: We present a case of hemophagocytic lymphohistiocytosis (HLH) with severe pulmonary complication and acute respiratory distress syndrome (ARDS) hospitalized in our intensive care unit (ICU) in 2014; distinctive trait of this case has been the challenging diagnosis, with a bone marrow biopsy always negative, the severe pulmonary complication with ARDS and severe pulmonary hypertension, and the ferritin temporal kinetics that precisely followed the clinical course of disease. PATIENT CONCERNS: A 32-year-old woman from the Philippines first diagnosed with upper airway infection, was subsequently hospitalized in infectious disease department and treated for community acquired pneumonia. DIAGNOSES: After clinical picture worsened with a profound respiratory insufficiency, the patient was intubated and transferred to our ICU. During this hospitalization, the clinical picture of fever, cutaneous rashes, lymphadenitis, hepatitis, leukopenia, anemia, hyperferritinemia, hypertriglyceridemia, high level of auto-antibodies, and low NK activity suggested an hemophagocytic lymphohistiocytosis syndrome, even if bone marrow biopsy was negative for hemophagocytosis. INTERVENTIONS: Immunosuppressive therapy with dexamethasone and etoposide was started, and the patient was discharged from ICU 4 months after admission. LESSONS: HLH is a rare disorder of the mononuclear phagocytic system, characterized by systemic proliferation of non- neoplastic histiocytes. The diagnosis is often challenging and not all of the diagnostic criteria may be present at the same time; this case shows how complex the diagnosis could be, how hematic ferritin levels could help in following the course of the disease, and the possibility of severe pulmonary complication either due to the disease itself and to possible sovra infections.
[Mh] Termos MeSH primário: Linfo-Histiocitose Hemofagocítica/complicações
Linfo-Histiocitose Hemofagocítica/diagnóstico
Insuficiência de Múltiplos Órgãos/diagnóstico
Insuficiência de Múltiplos Órgãos/etiologia
[Mh] Termos MeSH secundário: Adulto
Dexametasona/uso terapêutico
Diagnóstico Diferencial
Quimioterapia Combinada
Etoposídeo/uso terapêutico
Feminino
Glucocorticoides/uso terapêutico
Seres Humanos
Linfo-Histiocitose Hemofagocítica/tratamento farmacológico
Insuficiência de Múltiplos Órgãos/tratamento farmacológico
Inibidores da Topoisomerase II/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Topoisomerase II Inhibitors); 6PLQ3CP4P3 (Etoposide); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009198


  3 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193006
[Au] Autor:Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
[Ad] Endereço:Division of Hematology, The Ohio State University, Columbus, OH, USA.
[Ti] Título:A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
[So] Source:Br J Haematol;180(2):259-266, 2018 01.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Richter Syndrome, an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia (CLL), has a generally poor prognosis and anthracycline-based chemoimmunotherapy regimens designed to treat de novo diffuse large B-cell lymphoma achieve modest clinical benefit. R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) has demonstrated greater activity against aggressive B-cell histologies but has not been studied in Richter Syndrome. We conducted a retrospective cohort study of 46 Richter Syndrome patients treated with first-line R-EPOCH at our institution between 1 January 2006 and 31 May 2014. The median progression-free survival (PFS) was 3·5 months [95% confidence interval (CI): 2·0-7·6] and median overall survival (OS) was 5·9 months (95% CI: 3·2-10·3). Toxicity was high and 30% of patients died without progression or response. Patients with a complex CLL karyotype had significantly shorter PFS and OS (P = 0·005 and P = 0·002, respectively). Multivariable analysis identified complex CLL karyotype as the most significant predictor of decreased survival [Hazard ratio (HR) 2·72, 95% CI: 1·14-6·52, P = 0·025], adjusting for number of prior CLL treatments (P = 0·036). Richter Syndrome patients with complex CLL karyotype experience poor survival with R-EPOCH treatment and novel approaches are needed for these patients. In contrast, survival of patients without a complex CLL karyotype was similar to patients with de novo diffuse large B-cell lymphoma.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Leucemia Linfocítica Crônica de Células B/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Biomarcadores Tumorais
Ciclofosfamida/efeitos adversos
Ciclofosfamida/uso terapêutico
Progressão da Doença
Doxorrubicina/efeitos adversos
Doxorrubicina/uso terapêutico
Etoposídeo/efeitos adversos
Etoposídeo/uso terapêutico
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Cariótipo
Leucemia Linfocítica Crônica de Células B/genética
Leucemia Linfocítica Crônica de Células B/mortalidade
Masculino
Meia-Idade
Prednisona/efeitos adversos
Prednisona/uso terapêutico
Prognóstico
Estudos Retrospectivos
Rituximab/administração & dosagem
Resultado do Tratamento
Vincristina/efeitos adversos
Vincristina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 4F4X42SYQ6 (Rituximab); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15035


  4 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374714
[Au] Autor:Valan CD; Slagsvold JE; Halvorsen TO; Herje M; Bremnes RM; Brunsvig PF; Brustugun OT; Fløtten Ø; Levin N; Sundstrøm SH; Grønberg BH
[Ad] Endereço:Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway christine.valan@icloud.com.
[Ti] Título:Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
[So] Source:Anticancer Res;38(2):871-876, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). PATIENTS AND METHODS: Patients with a baseline CT scan available were analysed. Patients received four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). RESULTS: Median overall survival (OS) was 23.3 months in the whole cohort. N3-patients (n=37) had shorter survival than those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were no significant OS-differences between the N3 subcategories, but patients with metastases to two or more N3 regions had shorter survival than other N3 patients (13.4 vs. 19.9 months; p=0.011). CONCLUSION: There were no survival differences between the N3 subcategories, suggesting that all N3 disease should be considered as LD.
[Mh] Termos MeSH primário: Linfonodos/patologia
Carcinoma de Pequenas Células do Pulmão/patologia
Carcinoma de Pequenas Células do Pulmão/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Quimiorradioterapia
Cisplatino/administração & dosagem
Etoposídeo/administração & dosagem
Feminino
Seres Humanos
Metástase Linfática
Masculino
Meia-Idade
Estadiamento de Neoplasias
Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico
Carcinoma de Pequenas Células do Pulmão/radioterapia
Taxa de Sobrevida
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
6PLQ3CP4P3 (Etoposide); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  5 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29265182
[Au] Autor:Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xaiver AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
[Ad] Endereço:Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
[Ti] Título:R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
[So] Source:Br J Haematol;180(4):534-544, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is an uncommon subtype of non-Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique clinicopathological features. Historically, patients with PMBCL were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy ± involved field radiation. Since a phase II trial, published in April 2013, demonstrated excellent results using dose-adjusted (DA) R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), this treatment has gained popularity. We performed a retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011. Patients were stratified by frontline regimen, R-CHOP versus DA-R-EPOCH. 132 patients were identified from 11 contributing centres (56 R-CHOP and 76 DA-R-EPOCH). The primary outcome was overall survival. Secondary outcomes included progression-free survival, complete response (CR) rate, and rates of treatment-related complications. Demographic characteristics were similar in both groups. DA-R-EPOCH use increased after April 2013 (79% vs. 45%, P < 0·001), and there was less radiation use after DA-R-EPOCH (13% vs. 59%, P < 0·001). While CR rates were higher with DA-R-EPOCH (84% vs. 70%, P = 0·046), these patients were more likely to experience treatment-related toxicities. At 2 years, 89% of R-CHOP patients and 91% of DA-R-EPOCH patients were alive. To our knowledge, this represents the largest series comparing outcomes of R-CHOP to DA-R-EPOCH for PMBCL.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma de Células B/tratamento farmacológico
Neoplasias do Mediastino/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Monoclonais Murinos/efeitos adversos
Anticorpos Monoclonais Murinos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Terapia Combinada
Ciclofosfamida/efeitos adversos
Ciclofosfamida/uso terapêutico
Gerenciamento Clínico
Doxorrubicina/efeitos adversos
Doxorrubicina/uso terapêutico
Etoposídeo/efeitos adversos
Etoposídeo/uso terapêutico
Feminino
Seres Humanos
Linfoma de Células B/diagnóstico
Linfoma de Células B/mortalidade
Masculino
Neoplasias do Mediastino/diagnóstico
Neoplasias do Mediastino/mortalidade
Meia-Idade
Gradação de Tumores
Estadiamento de Neoplasias
Prednisona/efeitos adversos
Prednisona/uso terapêutico
Recidiva
Estudos Retrospectivos
Rituximab/administração & dosagem
Falha de Tratamento
Resultado do Tratamento
Vincristina/efeitos adversos
Vincristina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Murine-Derived); 0 (R-CHOP protocol); 4F4X42SYQ6 (Rituximab); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15051


  6 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390436
[Au] Autor:Jiang S; Wang G; Dong Y
[Ad] Endereço:Department of Medical Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
[Ti] Título:Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
[So] Source:Medicine (Baltimore);96(51):e9077, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Angiogenesis is a key factor for tumor growth and metastasis both in cancer and sarcoma. Endostar, a novel safe and well-tolerated recombinant human endostatin, can suppress the expression of VEGF and the activation of ERK, MAPK, and AKT, and then inhibit tumor progression. PATIENT CONCERNS: A pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion. DIAGNOSES: Osteosarcoma with pulmonary metastasis and malignant pleural effusion. INTERVENTIONS: Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles. OUTCOMES: The patient obtained pathologic complete remission and had been in progression-free survival up to now. LESSONS: Our experience could provide a treatment strategy for pediatric osteosarcoma patients with pulmonary metastasis and malignant pleural effusion.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Ósseas/tratamento farmacológico
Endostatinas/administração & dosagem
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/secundário
Osteossarcoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Neoplasias Ósseas/patologia
Criança
Etoposídeo/administração & dosagem
Seres Humanos
Ifosfamida/administração & dosagem
Neoplasias Pulmonares/cirurgia
Osteossarcoma/patologia
Osteossarcoma/secundário
Osteossarcoma/cirurgia
Derrame Pleural Maligno/tratamento farmacológico
Derrame Pleural Maligno/etiologia
Derrame Pleural Maligno/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endostatins); 0 (endostar protein); 6PLQ3CP4P3 (Etoposide); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009077


  7 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309885
[Au] Autor:Fei HR; Li ZJ; Ying-Zhang; Yue-Liu; Wang FZ
[Ad] Endereço:School of Pharmacology, Taishan Medical University, Chang Cheng Road, Taian 271016, PR China.
[Ti] Título:HBXIP regulates etoposide-induced cell cycle checkpoints and apoptosis in MCF-7 human breast carcinoma cells.
[So] Source:Gene;647:39-47, 2018 Mar 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Etoposide, an anticancer DNA topoisomerase II poison, plays an important role in the therapy for human cancers. Unfortunately, many cancers develop etoposide resistance and do not respond to chemotherapy, leading to difficulty in treatment and poor prognosis. In this study, we investigate the effects of HBXIP gene silencing on etoposide chemosensitivity in MCF-7 human breast cancer cells. We find that etoposide increases HBXIP expression and promotes mobilization of HBXIP to the nucleus in MCF-7 cells. Knockdown of HBXIP alleviates etoposide-induced G2/M or S phase arrest. Upregulation of p53 and p21 upon etoposide treatment is attenuated in HBXIP knock-down cells. Moreover, HBXIP gene silencing sensitizes etoposide-induced cell apoptosis and cleavage of caspase-9 and PARP in MCF-7 cells. Knockdown of HBXIP expression by RNAi abrogates the etoposide-activated ERK and Akt. These results indicate that HBXIP can modulate the etoposide sensitivity of MCF-7 cell lines and further implicate HBXIP as a target for human breast cancer.
[Mh] Termos MeSH primário: Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Apoptose/efeitos dos fármacos
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/metabolismo
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Etoposídeo/farmacologia
[Mh] Termos MeSH secundário: Caspase 9/metabolismo
Linhagem Celular Tumoral
Inibidor de Quinase Dependente de Ciclina p21/metabolismo
Feminino
Seres Humanos
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Células MCF-7
Poli(ADP-Ribose) Polimerases/metabolismo
Proteínas Proto-Oncogênicas c-akt/metabolismo
Proteína Supressora de Tumor p53/metabolismo
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (Cyclin-Dependent Kinase Inhibitor p21); 0 (HBXIP protein, human); 0 (Tumor Suppressor Protein p53); 6PLQ3CP4P3 (Etoposide); EC 2.4.2.30 (Poly(ADP-ribose) Polymerases); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 3.4.22.- (Caspase 9)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE


  8 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381934
[Au] Autor:He M; Jia J; Zhang J; Beejadhursing R; Mwamaka Sharifu L; Yu J; Wang S; Feng L
[Ad] Endereço:Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China.
[Ti] Título:Pregnancy-associated hemophagocytic lymphohistiocytosis secondary to NK/T cells lymphoma: A case report and literature review.
[So] Source:Medicine (Baltimore);96(47):e8628, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Hemophagocytic lymphohistiocytosis (HLH) occurs primarily in pediatric population, or secondary to malignancy, infection, or autoimmune disease. This disease is rare and prognosis is generally poor. Only a small number of cases during pregnancy have been reported in literature. PATIENT CONCERNS: We report a case of pregnancy-associated HLH secondary to natural killer (NK)/T cells lymphoma. She was admitted at 30 weeks and 3 days of pregnancy with complaints of abdominal pain and fever as high as 39.2°C. The patient was found to have splenomegaly, pancytopenia, and acute hepatic failure. DIAGNOSES: A subsequent bone marrow biopsy revealed focal hemophagocytosis and atypical lymphoid cells. The splenic pulp also contained a large number of tissue cells proliferating and devouring mature red blood cells, lymphocytes, and cell debris. On the basis of these findings, we diagnosed the case as pregnancy-associated hemophagocytic lymphohistiocytosis secondary to NK/T cells lymphoma. INTERVENTIONS: Treatment consisted with dexamethasone and etoposide in combination with rituximab. OUTCOMES: Due to timely termination of pregnancy, the neonate was in good condition. However, the patient died on the 18th day postoperation due to multiorgan failure. LESSONS: We recommend that HLH be considered as differential diagnosis in a pregnant patient complaining of persistent fever, cytopenia, or declining clinical condition despite delivery of the baby. Prompt diagnosis and treatment is essential and fetal outcomes should also be considered. The decision to terminate a pregnancy and initiate chemotherapy during pregnancy with malignancy-associated HLH (M-HLH) needs to be further investigated in a larger cohort.
[Mh] Termos MeSH primário: Dexametasona/administração & dosagem
Etoposídeo/administração & dosagem
Linfo-Histiocitose Hemofagocítica
Linfoma
Células T Matadoras Naturais/patologia
Complicações Neoplásicas na Gravidez
Rituximab/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/administração & dosagem
Exame de Medula Óssea/métodos
Diagnóstico Diferencial
Evolução Fatal
Feminino
Seres Humanos
Linfo-Histiocitose Hemofagocítica/diagnóstico
Linfo-Histiocitose Hemofagocítica/tratamento farmacológico
Linfo-Histiocitose Hemofagocítica/etiologia
Linfo-Histiocitose Hemofagocítica/fisiopatologia
Linfoma/complicações
Linfoma/patologia
Gravidez
Complicações Neoplásicas na Gravidez/diagnóstico
Complicações Neoplásicas na Gravidez/patologia
Complicações Neoplásicas na Gravidez/fisiopatologia
Complicações Neoplásicas na Gravidez/cirurgia
Resultado da Gravidez
Baço/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 4F4X42SYQ6 (Rituximab); 6PLQ3CP4P3 (Etoposide); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008628


  9 / 15602 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173760
[Au] Autor:Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
[Ad] Endereço:Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK.
[Ti] Título:Targeting DNA damage in SCLC.
[So] Source:Lung Cancer;114:12-22, 2017 Dec.
[Is] ISSN:1872-8332
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has been no change to the standard platinum and etoposide regimen for first line treatment developed in the 1970's. The exceptionally high number of genomic aberrations observed in SCLC combined with the characteristic rapid cellular proliferation results in accumulation of DNA damage and genomic instability. To flourish in this precarious genomic context, SCLC cells are reliant on functional DNA damage repair pathways and cell cycle checkpoints. Current cytotoxic drugs and radiotherapy treatments for SCLC have long been known to act by induction of DNA damage and the response of cancer cells to such damage determines treatment efficacy. Recent years have witnessed improved understanding of strategies to exploit DNA damage and repair mechanisms in order to increase treatment efficacy. This review will summarise the rationale to target DNA damage response in SCLC, the progress made in evaluating novel DDR inhibitors and highlight various ongoing challenges for their clinical development in this disease.
[Mh] Termos MeSH primário: Dano ao DNA/genética
Neoplasias Pulmonares/tratamento farmacológico
Rad51 Recombinase/antagonistas & inibidores
Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico
[Mh] Termos MeSH secundário: Aurora Quinases/uso terapêutico
Azepinas/uso terapêutico
Benzimidazóis/uso terapêutico
Carbolinas/uso terapêutico
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Pontos de Checagem do Ciclo Celular/genética
Proliferação Celular/efeitos dos fármacos
Proliferação Celular/genética
Citotoxinas/uso terapêutico
Dano ao DNA/efeitos dos fármacos
Reparo do DNA
Etoposídeo/uso terapêutico
Instabilidade Genômica/efeitos dos fármacos
Instabilidade Genômica/genética
Compostos Heterocíclicos de 4 ou mais Anéis/uso terapêutico
Seres Humanos
Neoplasias Pulmonares/genética
Terapia de Alvo Molecular/métodos
Ftalazinas/uso terapêutico
Piperazinas/uso terapêutico
Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico
Inibidores de Proteínas Quinases/uso terapêutico
Pirimidinas/uso terapêutico
Rad51 Recombinase/uso terapêutico
Carcinoma de Pequenas Células do Pulmão/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Azepines); 0 (Benzimidazoles); 0 (Carbolines); 0 (Cytotoxins); 0 (Heterocyclic Compounds, 4 or More Rings); 0 (MLN 8237); 0 (PM 01183); 0 (Phthalazines); 0 (Piperazines); 0 (Poly(ADP-ribose) Polymerase Inhibitors); 0 (Protein Kinase Inhibitors); 0 (Pyrimidines); 01O4K0631N (veliparib); 6PLQ3CP4P3 (Etoposide); 9QHX048FRV (talazoparib); EC 2.7.11.1 (Aurora Kinases); EC 2.7.7.- (Rad51 Recombinase); WOH1JD9AR8 (olaparib)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  10 / 15602 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29248013
[Au] Autor:Ghalleb M; Bouzaiene H; Slim S; Hadiji A; Hechiche M; Ben Hassouna J; Rahal K
[Ad] Endereço:Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunis, Tunisia.
[Ti] Título:Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report.
[So] Source:J Med Case Rep;11(1):350, 2017 Dec 17.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Malignant ovarian germ cell tumor is a rare type of disease, which generally has a good prognosis due to the high chemosensitivity of this type of tumor. Fertility preservation is an important issue because malignant ovarian germ cell tumor commonly affects young women. Although conservation is the standard for early stage, it becomes more debatable as the disease progresses to more advanced stages. AIM: Report the case of a patient with an International Federation of Gynecology and Obstetrics Stage IIIc malignant ovarian germ cell tumor, who had conservative surgery and chemotherapy with a good fertility outcome. CASE PRESENTATION: A 23-year-old North African woman with a left malignant ovarian germ cell tumor stage IIIc was treated by left adnexectomy and omentectomy followed by chemotherapy. A 15-year follow-up showed no signs of relapse, and she completed three full-term natural pregnancies. CONCLUSIONS: Malignant ovarian germ cell tumor is a rare ovarian tumor with a good prognosis. It is usually associated with a good fertility outcome in early stages. However, due to the rarity of the disease in advanced stages, the fertility outcome for this group of patients is not clear. This lack of data surrounding advanced stages points to the need for a meta-analysis of all published cases.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Preservação da Fertilidade/métodos
Neoplasias Embrionárias de Células Germinativas/cirurgia
Neoplasias Ovarianas/cirurgia
Ovariectomia/métodos
Neoplasias Peritoneais/cirurgia
[Mh] Termos MeSH secundário: Bleomicina/uso terapêutico
Quimioterapia Adjuvante
Cisplatino/uso terapêutico
Etoposídeo/uso terapêutico
Feminino
Seres Humanos
Estadiamento de Neoplasias
Neoplasias Embrionárias de Células Germinativas/patologia
Omento/cirurgia
Neoplasias Ovarianas/patologia
Neoplasias Peritoneais/secundário
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
11056-06-7 (Bleomycin); 6PLQ3CP4P3 (Etoposide); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171218
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1516-8



página 1 de 1561 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde